iShares US Pharmaceuticals ETF
94 hedge funds and large institutions have $78.9M invested in iShares US Pharmaceuticals ETF in 2020 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 28 reducing their positions, and 10 closing their positions.
24,167% more call options, than puts
Call options by funds: $728K | Put options by funds: $3K
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
3% more funds holding
Funds holding: 91 → 94 (+3)
4.72% less ownership
Funds ownership: 72.49% → 67.77% (-4.7%)
6% less capital invested
Capital invested by funds: $83.7M → $78.9M (-$4.8M)
21% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CFGS
Concourse Financial Group Securities
Birmingham,
Alabama
|
+$3.63M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.08M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$565K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$499K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
+$387K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5.15M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.13M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$1.15M |
| 4 |
SRSA
S.R. Schill & Associates
Mercer Island,
Washington
|
-$990K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$953K |
IHE Hedge Fund Activity: Q3 2020 in Review
94 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2020, worth a combined $78.9M — down 5.7% from $83.7M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IHE positions and 10 closed out — a net gain of 4 holders — while 22 added to existing stakes and 28 trimmed.
The largest buyer was Concourse Financial Group Securities, adding an estimated $3.63M. The largest seller was Royal Bank of Canada, cutting an estimated $5.15M.
- 94 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2020, up from 91 in Q2 2020.
- Funds reported $78.9M of iShares US Pharmaceuticals ETF stock for Q3 2020, down 5.7% quarter-over-quarter.
- 14 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2020 and 10 closed out, a net change of +4 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q3 2020 was Concourse Financial Group Securities, an estimated $3.63M added.
- The largest iShares US Pharmaceuticals ETF seller in Q3 2020 was Royal Bank of Canada, an estimated $5.15M sold.
Based on aggregated 13F filings for Q3 2020.